ERBB2/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers

ERBB2/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers

Abstract Background The HOXB13/IL17RB gene expression biomarker has been shown to predict response to adjuvant and extended endocrine therapy in patients with early-stage ER+ HER2- breast tumors. HOXB13 gene expression is the primary determinant driving the prognostic and endocrine treatment-predict...

Full description

Saved in:
Bibliographic Details
Main Authors: Irene Rin Mitsiades, Maristela Onozato, A. John Iafrate, Daniel Hicks, Doğa C. Gülhan, Dennis C. Sgroi, Esther Rheinbay
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Breast Cancer Research
Subjects:
HOXB13
ERBB2
Co-amplification
Breast cancer
BRCA1
Online Access:https://doi.org/10.1186/s13058-024-01943-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13058-024-01943-1

Similar Items